Lack of phototoxicity potential with delafloxacin in healthy male and female subjects: comparison to lomefloxacin

R. S. Dawe, J. Ferguson, S. Ibbotson, L. Lawrence, S. Paulson, E. Duffy, S. Cammarata (Lead / Corresponding author)

Research output: Contribution to journalArticlepeer-review

24 Citations (Scopus)
69 Downloads (Pure)


Aims: Delafloxacin is a fluoroquinolone antibiotic recently approved by the FDA for treatment of acute bacterial skin and skin structure infections (ABSSSI). Delafloxacin was assessed for phototoxicity potential compared with a known phototoxic fluoroquinolone. Methods: A Phase 1, investigator-blind, placebo/active-controlled, randomized, parallel-group study was conducted in 52 healthy male and female volunteers who received 200 or 400 mg of oral delafloxacin, 400 mg oral lomefloxacin or placebo once daily for 6 days. This study evaluated the photosensitizing potential and possible wavelength dependency of delafloxacin by comparing the response of the skin to ultraviolet A (UVA), ultraviolet B (UVB) and visible radiation prior to and during administration of delafloxacin, lomefloxacin as a positive control, or placebo. Adverse events were monitored throughout the study. Results: Forty-seven subjects completed six days of dosing, and no evidence of phototoxicity was seen with delafloxacin. Delafloxacin at 200 and 400 mg day -1 and placebo did not demonstrate differences in percent change from baseline in minimal erythema dose at all tested wavelengths (295-430 nm) by monochromator and solar simulator. Lomefloxacin, the positive control, had statistically significant differences (p < 0.05) at UVA wavelengths of 335 and 365 ± 30 nm 24 hours after radiation exposure (maximum response). The phototoxic index results were significantly higher for lomefloxacin at 335 nm and 365 nm compared to placebo and delafloxacin. Conclusions: 200 and 400 mg of delafloxacin administered for 6 days were well tolerated in healthy adult volunteers. Delafloxacin and placebo failed to demonstrate a phototoxic effect but lomefloxacin, the positive control, demonstrated moderate phototoxicity.

Original languageEnglish
Pages (from-to)773-780
Number of pages8
JournalPhotochemical & Photobiological Sciences
Issue number6
Early online date27 Apr 2018
Publication statusPublished - 1 Jun 2018


  • Phototoxicity
  • delafloxacin
  • fluoroquinolone
  • Structure-activity-relationship
  • Anti-Bacterial Agents/administration & dosage
  • Administration, Oral
  • Photosensitizing Agents/administration & dosage
  • Humans
  • Middle Aged
  • Male
  • Healthy Volunteers
  • Fluoroquinolones/administration & dosage
  • Young Adult
  • Maximum Tolerated Dose
  • Ultraviolet Rays
  • Light
  • Adolescent
  • Adult
  • Female
  • Molecular Structure
  • Skin/drug effects
  • Dermatitis, Phototoxic

ASJC Scopus subject areas

  • Physical and Theoretical Chemistry


Dive into the research topics of 'Lack of phototoxicity potential with delafloxacin in healthy male and female subjects: comparison to lomefloxacin'. Together they form a unique fingerprint.

Cite this